Clinical Trial Update: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a quadruplet regimen of isatuximab, pomalidomide, elotuzumab, and dexamethasone for relapsed/refractory multiple myeloma; status is act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Empliciti (elotuzumab)
• Pomalyst (pomalidomide)
• SARCLISA (isatuximab)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING